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Abstract 
We investigated the effect of the soluble Nogo66 receptor (sNgR-Fc) on the protection of 
cortical axons after cortical infarction in rats. The cortical infarction was induced by 
photothrombotic cortical injury (PCI) in Sprague Dawley rats, after which sNgR-Fc was 
injected into the lateral ventricle. The ipsilesional cortices were harvested for analyses using 
histochemical and transmission-electron microscope techniques. The involved signaling 
pathways, which include RhoA, JNK, c-JUN and ATF-2, were detected by Western blot. 
Serious pathologies were found in the brains of the rats after injury, including edemas in the 
axoplasms of axons that have no medulla sheath and a thickening or shrinkage in the sheath 
of the axons that have medulla sheathes. However, these pathologies improved after sNgR-Fc 
treatment. The levels of GTP-RhoA, p-JNK, p-c-JUN and p-ATF-2 in the PCI group were 
increased when compared with their levels in the sham-operation group (P < 0.05), and 
animals receiving the sNgR-Fc treatment showed lower expression levels of these proteins 
when compared with the sham-operation group (P < 0.05). Our results suggest that sNgR-Fc 
can alleviate the pathological changes of axons following cortical infarction via decreasing 
the activation of RhoA/JNK signaling pathways. 
Key words: Nogo-66 receptor; Axon; Cortical infarction; Regeneration; Signal pathway 
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Introduction 
A brain infarction (also known as an ischemic stroke) is caused by the blockage of a cerebral 
artery by a blood clot, which results in the following effects: a critical reduction in blood flow, 
ischemia, anoxia, and, finally, ischemic necrosis or encephalomalacia in the brain. This 
condition is characterized clinically by high morbidity, high mortality, high disability rate, 
high recurrence rates, and it is difficult to treat. Because our population is aging, stroke is 
becoming a more serious threat and an urgent medical problem. Previous studies have shown 
that the central nerve system cannot regenerate after injury, as a result of factors that include 
the insufficiency of neural progenitor cells (NPCs) and a microenvironment that inhibits the 
regeneration of neurons
 
[1]. Recent studies have demonstrated that the inhibition of axon 
regeneration after injuries to the central nervous system (CNS) were associated with several 
CNS myelin proteins, including Nogo-A, myelin-associated glycoprotein (MAG), and 
oligodendrocyte myelin glycoprotein (OMgp). These three proteins bind to the Nogo-66 
receptor (NgR1), which then leads to the downstream activation of RhoA (Ras homolog gene 
family, member A) via two transmembrane proteins, LINGO-1 and p75; these proteins inhibit 
the activity in neurons and their axons [2–4]. Jun N-terminal kinases (JNKs) are intracellular 
molecules related to stress stimuli. The activation of these molecules mediates many types of 
injury-induced apoptosis and plays a role in the regeneration of axons. However, the role of 
the JNK-signaling pathway in the presence of a brain infarction is still unclear. The 
administration of sNgR-Fc, a recombinant rat soluble NgR-Fc fusion protein
 
[5], has been 
found to block the interaction of myelin proteins with NgR1 effectively and to promote the 
regeneration of axons in rodent models of CNS injuries such as spinal cord injury [6–10]. A 
previous study has shown that anti-Nogo-A antibody promoted the behavioral outcome and 
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corticospinal plasticity in a rat stroke model [11]. In this study, we established a stroke model 
in rats and observed the effects of sNgR-Fc on the axonal pathology and the involved 
RhoA/JNK signaling pathways after cortical infarction. 
 
Experimental Procedure 
Animals 
The animal experiments were approved by the Committee for the Use of Live Animals in 
Teaching and Research at the Sun Yat-sen University. All of the experiments were performed 
in a fully randomized and blinded fashion.  
Photothrombotic cortical injury  
Photothrombotic ischemia was induced in the rat parietal cortex using previously described 
methods [9,11,12] with the modifications as outlined below. Twenty seven male SD rats 
weighing 250 g were anesthetized by an intraperitoneal injection of ketamine (80 mg/kg) and 
xylazine (8 mg/kg). Dilute Rose-Bengal in saline (40 mg/kg body weight) was infused into 
the femoral vein. The portion of the skull exposed at 3 mm posteriorly to the bregma and 3 
mm laterally from the midline was illuminated with a cold, white light beam (Volpi Intralux 
6000, 150 W; Volpi AG, Schlieven, Switzerland) for 8 min at maximum output via a 
fiber-optic bundle with a 10 mm aperture. The animals were randomly grouped into 
sham-operation (operation + Rose-Bengal), PBS (operation + Rose-Bengal + PBS), or 
sNgR-Fc (operation + Rose-Bengal + sNgR-Fc) groups (n = 9 for each group). A solution of 
sNgR-Fc (400 μg/kg body weight) in 10μl PBS or equivalent PBS was only once injected 
into the ipsilateral ventricle using a 26-gauge sterile microsyringe 24 h after photothrombotic 
cortical injury [11]. The site of injection was at 1 mm posteriorly to the bregma and 1.5 mm 
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laterally from the midline, and the depth of injection was about 3.5~4.0 mm. For each group, 
the whole cerebrum of 3 animals was collected 24 h after injury for tissue staining. The 
ipsilateral cortex of peripheral penumbra at 7 mm posteriorly to the bregma and 3 mm 
laterally from the midline of rats was collected at 27 d after injury for electron microscopy 
examination (n = 3 for each group) and for Western blotting (n = 3 for each group). 
 
Triphenyltetrazolium chloride staining 
To evaluate the extent of cortical infarction, we used 2, 3, 5-Triphenyltetrazolium chloride 
(TTC) to assess cerebral injury. At 24 h after PCI, the animals were sacrificed using an 
overdose of pentobarbital sodium (150 mg/kg, Alcon-Couvreur, Rijksweg, Puurs, Belgium). 
The brains were removed immediately and then were chilled at −30 °C for 4 min to slightly 
freeze the tissue. Two-mm coronal sections from the olfactory bulb to the cerebellum were 
prepared, stained with 1.5% TTC (Genetime) at 37 °C for 30 min, and fixed in 10% buffered 
formalin solution.  
Transmission electron microscopy 
Seven days after PCI, the peripheral penumbra at 7 mm posteriorly to the bregma and 3 mm 
laterally from the midline on the injury side was removed and immediately cut into 0.5 cm
3
 
cubes at 0 °C, fixed with 4% paraformaldehyde for 4 h, and washed with PBS. Then, the 
tissue was fixed with 2% osmic acid for 2 h, washed with pure water, dehydrated with a 
mixture of ethanol, propylene oxide, and resin, embedded in pure resin, and ultramicrocut 
and stained with uranyl acetate and lead citrate [13, 14]. The sections were observed under an 
HE-800 transmission electron microscope (Hitachi, Japan).  
Western blotting 
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The cortex from the injury side was collected at 7 days after injury and homogenized in a 
lysis buffer (in mM: Tris, 10, pH 7.4; NaCl, 150; EDTA, 1; EGTA, 1; 10% protease inhibitor, 
1% phosphatase inhibitor), and incubated on ice for 30 min. The protein lysate was then 
centrifuged at 13,500 rpm for 30 min at 4 ℃. The supernatant was aliquoted and stored at 
−80 °C until its use. The supernatant was measured for its protein concentration using a 
Bio-Rad DC Protein Assay Kit (Bio-Rad Laboratories, CA, USA). A 40 μg aliquot of protein 
from each sample was subjected to 5–12% SDS–polyacrylamide gel electrophoresis and 
transferred onto a PVDF membrane. Each membrane was blocked with 5% non-fat milk and 
2% bovine serum albumin in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 h 
at room temperature and then probed with rabbit anti-p-JNK (Cell Signaling Technology, 
MA, USA), anti-p-c-JUN (Cell Signaling Technology), p-ATF-2 (Cell Signaling 
Technology), total-JNK (Cell Signaling Technology) and total-RhoA antibodies at 4 °C 
overnight. As a gel loading control, β-actin was used. After washing, the membranes were 
incubated for 2 h with horseradish peroxidase-conjugated goat anti-rabbit antibody (1:2000; 
DakoCytomation, Denmark). Its immunoreactivity was visualized using the Amersham 
enhanced chemiluminescence kit (Amersham, Piscataway, NJ, USA). The protein loading 
was controlled using the goat antibody against β-actin (C-11; Santa Cruz Biotechnology). 
The quantification of the results was performed by densitometry, and the results were 
analyzed as total integrated densitometric values (arbitrary units). The protein GTP-RhoA 
was pulled down using a RhoA activation assay kit, according to the manufacturer's 
instruction (Cytoskeleton, Denver, CO, USA) and assayed by Western blotting using an 
antibody against RhoA (Cytoskeleton). All experiments for Western blotting were performed 
with 3 animals in each group, and the samples were run on the gels as individual animals. 
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Data and statistical analysis 
The values are presented as the mean ± SD. The statistical analyses was performed 
using Student’s t-test for comparisons between two groups or the one-way analysis of 
variance (ANOVA) followed by post-hoc tests (Student-Neuman-Keuls) for comparisons of 
more than two groups. The data were analyzed statistically with the software SPSS 12.0. The 
significance level was set at P < 0.05. 
 
Results 
Measurement of brain infarct volume and identification of blood brain barrier integrity 
After TTC staining, the rats in the sham group did not appear to have any infarctions (Fig. 
1b). However, the right parietal lobes of the rats 24 h after PCI presented pale infarctions that 
were bowl-shaped, with the bottom pointing to the lateral ventricle; these infarctions affected 
the entire cortex. The total infarct volumes were 297.1 ± 23.4 μl in the PBS group and 
285.4 ± 19.7 μl for the sNgR-Fc group respectively before the treatment. The locations of 
the infarctions were stable, and the infarctions showed similar volumes to those in the rats 
(Fig. 1). 
Pathological changes of axons 
The morphology of ischemic penumbra on the injury side was evaluated using TEM at 7 days 
after PCI. Compared with the normal axons observed in the sham group (Fig. 2a), more 
serious pathologies were observed in the PCI group (Fig. 2b). For the axons without a 
medulla sheath, many edemas, dilutions of cytoplasmic matrices, and axonal fusions or 
dissolutions were found. Occasionally, we observed that oligodendrocytes appeared to 
“swallow” the axons (Fig. 2b). For axons with a medulla sheath, compared with the sham 
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group, thickening or shrinking was more in the axoplasm of the fibers, and amyloidosis and 
swollen axons were observed at a higher rate. In addition, the axolemma were found to be 
separated from the inner layers of the myelin (Fig. 2e). In addition, there were only minor 
pathological changes, including slight nuclear edemas with complete nucleoli, slightly 
swollen mitochondria, and slightly widened endoplasmic reticula with complete ribosomes 
and Golgi bodies. In unmyelinated axons, there were some axonal edemas, axonal 
deformities, and dilutions of cytoplasmic matrices; in addition, there were no axonal fusions 
or cytophagic effects of oligodendrocytes (Fig. 2c). In myelinated axons, the morphology of 
axons was almost normal. There was little demyelination and no amyloidosis of the myelin 
sheath was found (Fig. 2f). Compared with normal synapses (Fig. 2g), the synaptic cleft 
widened, and there was edema in the PBS group (Fig. 2h). However, no clear edema or 
widening of the synaptic cleft was observed in the group that received the sNgR-Fc treatment 
(Fig. 2i). 
sNgR-Fc inhibited RhoA signal pathway 
The level of GTP-RhoA in the PBS group was significantly higher than that in the 
sham-operation group (P <0.05). After treatment with sNgR-Fc, the level of GTP-RhoA was 
significantly decreased. Moreover, the level of Total-RhoA was not different among the three 
groups (Fig.3, Table 1). These data indicate that sNgR-Fc could decrease the activation of 
RhoA. 
sNgR-Fc inhibit the activation of SAPK/JNK signal pathway 
The levels of p-JNK1, 2 and its downstream targets, p-c-JUN and p-ATF-2, in the cortex 
around the infarcts in the PCI group were significantly higher compared with those in the 
sham operation group (P < 0.05). In contrast, the cortex in the sNgR-Fc-treated group showed, 
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on average, reductions in the levels of p-JNK1, 2, p-c-JUN and p-ATF-2 to their basal levels 
(P < 0.05). The levels of total JNK1, 2 were not different among the three groups (P > 0.05). 
These results demonstrate that the cortical infarction injury activates the SAPK/JNK signal 
pathway and that treatment with sNgR-Fc has the potential to decrease or prevent this 
activation (Fig.3, Table 1). 
 
Discussion 
Watson et al reported a stroke model induced by a photochemical method in 1985 [12]. The 
principle underlying this model was based on a photochemical reaction. Following the 
injection of a potent photosensitive agent into rats, ischemic lesions were formed by 
irradiating the left parietal convexities of the exposed skulls under a light with a specific 
wavelength. Free radicals were released, damaging the endothelium of the cerebral vessels 
and inducing platelet aggregation. Furthermore, this pathology causes thrombosis in cerebral 
parenchymal vessels and results in irreversible hypoxic-ischemic brain damage (HIBD). 
Because of the advantages of a stable location and infarction volume, a low mortality rate, 
and a good replication rate, the stroke model is widely used in current studies of brain injury. 
In this study, we successfully induced a cortical ischemic infarction model in rats in which 
the BBB was also damaged. The primary pathological features of stroke were induced, and 
the volumes of infarction were consistent. No infarction and no burn were observed in the 
sham-group, indicating that the light stimulation alone did not induce the infarction and that it 
acts as a good control. 
Delayed neuron death (DND) is an important pathology of cerebral ischemia and 
cerebral degenerative disease. Cell apoptosis was the primary DND pattern after an acute 
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HIBD, which aggravated the injury of sub-acute or chronic cerebral infarction [15, 16]. In our 
study, axonal pathologies were observed via the TEM at 7 days after PCI, including many 
edemas in the axoplasm of axons that have no medulla sheath, and thickening or shrinkage in 
the sheaths of the axons that have a medulla sheath. However, these conditions improved 
after sNgR-Fc treatment. The administration of the soluble NgR1 fusion protein (sNgR-Fc) 
effectively blocked the interaction of myelin molecules with NgR1 and promoted axon 
sprouting and functional recovery after spinal cord injuries[7–9], or dorsal root rhizotomy[10]. 
A previous study found that Nogo-A is involved in the secondary axonal degeneration of the 
thalamus with cerebral infarction in hypertensive rats [17] and after a focal ischemic stroke 
[18]. Anti–Nogo-A antibody improved behavioral outcome and corticospinal plasticity but 
did not decrease the infarct volume after experimental stroke [11]. In this study, sNgR-Fc did 
not cause any difference on infarct volume, but still provided protection of axons as observed 
in TEM. 
Nogo-A, MAG and OMgp were considered to be the inhibitory factors of axonal 
regeneration in the CNS. NgR1 mediates their inhibitory effect via two co-receptors, p75 and 
Lingo-1, and transduces the signals via RhoA and its downstream pathways [19, 20]. In this 
study, the level of the GTP-RhoA protein in the model group was significantly higher than 
that of the sham-operation group. With the treatment of sNgR-Fc, the level of the GTP-RhoA 
protein was significantly decreased, suggesting that sNgR-Fc may promote axonal recovery 
by preventing the activation of RhoA after cerebral infarction.  
The stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) signaling 
pathway is a powerful signaling pathway under the stresses of ultraviolet light, radiation and 
inflammation [21–23]. In publications on neuronal apoptosis, some of the proteins in the 
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mitogen-activated protein kinases (MAPK) signaling pathways have been well-studied in 
recent years. The MAPK signaling pathway is a family of serine/threonine kinases that 
include three members: the extracellular signal-regulated protein kinases (ERK), JNK and 
p38 [24]. The JNK/SAPK and p38 are induced by cellular stress and some of the cytokines. 
The JNK protein can be activated by many stress stimulators, such as lipopolysaccharide 
(LPS), tumor necrosis factor-α(TNF-α), interleukin (IL)-1 or ultraviolet light. Activation of 
the JNK signaling pathway is related to cell apoptosis [24]. Following its activation, JNKs 
may phosphorylate specific sites of some of the transcription factors, such as ATF-2, SAP-1 
and Elk-1, and increase the expression of genes, subsequently increasing the synthesis of 
proteins that may participate in the apoptosis pathway and cause cell death [25]. We found 
high levels of p-JNK，p-c-JUN and p-ATF-2 after stroke injury, indicating that cortical 
infarction activates the SAPK/JNK signal pathway and leads to the pathology of tissues and 
cells. The administration of sNgR-Fc decreased the activation of those proteins, suggesting 
that sNgR-Fc has the potential to prevent or decrease the activation of the SAPK/JNK signal 
pathway. We previously identified that sNgR-Fc binds to Nogo66, OMgp, and MAG [9] and 
inhibited the Nogo66-NgR interaction [6]. sNgR-Fc may protect axons by inhibiting the 
interaction of Nogo-A-NgR1 after stroke injury, decreasing the activation of RhoA and JNK. 
A schematic diagram illustrating the proposed mechanism for sNgR-Fc on axons in stroke is 
shown in Figure 4: In normal conditions, the cortex expresses low levels of Nogo-A and 
NgR1. However, cortical infarction under stroke injury increases the expression of Nogo-A 
and NgR1. Nogo-A activates RhoA and JNK signaling pathways via interacting with NgR1 
and then results in pathological changes on axons. sNgR-Fc perturbs the interaction of 
Nogo-A and NgR1, decreases the activation of RhoA and JNK signaling pathways and 
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relieving the pathological changes of axons.  
RhoA regulates the intracellular microfilament associated with cell proliferation through a 
series of complex mechanisms [26]. Previous studies have observed that RhoA stimulates Jun 
expression through the Rho-associated kinase (ROCK), which phosphorylates c-Jun and 
ATF2 after binding to the c-Jun promoter [27]. In this study, we observed that changes in the 
expression of p-JNK, p-c-Jun and p-ATF-2 were consistent with changes in the GTP-RhoA 
level following both the cerebral infarction and the sNgR-Fc treatment. These findings 
suggest that sNgR-Fc can relieve the axonal pathology partially by decreasing the activation 
of the SAPK/JNK signal pathways. 
In summary, pathological changes in axons were induced by the cerebral 
hypoxia-ischemia for an extended period after the cortical infarction. This phenomenon may 
be associated with the activation of RhoA/ROCK/JNK/c-Jun signaling pathways. We 
determined that an NgR1 antagonist, sNgR-Fc, alleviated axonal pathology changes and 
prevented the activation of RhoA/ROCK/JNK/c-Jun signaling pathways. Further studies 
should be performed before this treatment is used in a clinical study. 
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Figure Legends 
Figure 1. The morphology and characteristics of the rat brain after a stroke induced by 
photothrombotic cortical injury. (a) Representative photographs of the coronal brain 
sections stained with 2,3,5-triphenyltetrazolium chloride in rats, (b) sham-operated rats, (c) 
and photothrombotic cortical injury (PCI) rats. White indicates the infarct area (arrow).  
 
Figure 2. The protective effect of sNgR-Fc on axon neurons under transmission electron 
microscope after stroke injury. Ultrastructural appearances of morphology of axons in 
sham-operated, PBS and sNgR-Fc groups: (a) Normal unmyelinated axons in sham-operated 
group; (b) Extensive edema, axon deformity, dilution of cytoplasmic matrices and axonal 
fusion in stroke model; (c) Slight edema and dilution of cytoplasmic matrices with the 
treatment of sNgR-Fc in stroke model; (d) Normal myelinated axons in sham-operated group; 
(e) Thickening, shrinking or amyloidosis was more in stroke model; (f) Little demyelination 
and no amyloidosis of the myelin sheath were found with the treatment of sNgR-Fc in stroke 
model; (g) Normal synapses in the sham-operated group; (h) Widened and swollen synaptic 
cleft in stroke model; (i) Approximately normal synapses with the treatment of sNgR-Fc in 
stroke model. Arrows show the changes in axons. 
 
Figure 3. The RhoA, SAPK/JNK signaling pathways after stroke injury and with the 
treatment of sNgR-Fc under Western blotting. The levels of p-JNK，p-c-JUN, p-ATF-2 
and GTP-RhoA increased after stroke injury. Treatment with sNgR-Fc decreased the levels of 
p-JNK, p-c-JUN, p-ATF-2 and GTP-RhoA to normal levels. 
 
Figure 4. The diagram of the signaling pathways involved in the sNgR-Fc on axons after 
stroke injury. In the normal condition, there is low level of Nogo-A and NgR1 in the cortex. 
However, the expression of Nogo-A and NgR1 is increased under stroke injury. The increased 
Nogo-A binds with NgR1 to activate the downstream pathways of RhoA and JNK, and then 
results in axonal pathology. The treatment of sNgR-Fc inhibits the interaction of Nogo-A and 
NgR1, decreases the activation of RhoA and JNK signaling pathways and then relieves 
axonal pathology.  
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 Abstract 
We investigated the effect of the soluble Nogo66 receptor (sNgR-Fc) on the protection of 
cortical axons after cortical infarction in rats. The cortical infarction was induced by 
photothrombotic cortical injury (PCI) in Sprague Dawley rats, after which sNgR-Fc was 
injected into the lateral ventricle. The ipsilesional cortices were harvested for analyses using 
histochemical and transmission-electron microscope techniques. The involved signaling 
pathways, which include RhoA, JNK, c-JUN and ATF-2, were detected by Western blot. 
Serious pathologies were found in the brains of the rats after injury, including edemas in the 
axoplasms of axons that have no medulla sheath and a thickening or shrinkage in the sheath 
of the axons that have medulla sheathes. However, these pathologies improved after sNgR-Fc 
treatment. The levels of GTP-RhoA, p-JNK, p-c-JUN and p-ATF-2 in the PCI group were 
increased when compared with their levels in the sham-operation group (P < 0.05), and 
animals receiving the sNgR-Fc treatment showed lower expression levels of these proteins 
when compared with the sham-operation group (P < 0.05). Our results suggest that sNgR-Fc 
can alleviate the pathological changes of axons following cortical infarction via decreasing 
the activation of RhoA/JNK signaling pathways. 
Key words: Nogo-66 receptor; Axon; Cortical infarction; Regeneration; Signal pathway 
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 Introduction 
A brain infarction (also known as an ischemic stroke) is caused by the blockage of a cerebral 
artery by a blood clot, which results in the following effects: a critical reduction in blood flow, 
ischemia, anoxia, and, finally, ischemic necrosis or encephalomalacia in the brain. This 
condition is characterized clinically by high morbidity, high mortality, high disability rate, 
high recurrence rates, and it is difficult to treat. Because our population is aging, stroke is 
becoming a more serious threat and an urgent medical problem. Previous studies have shown 
that the central nerve system cannot regenerate after injury, as a result of factors that include 
the insufficiency of neural progenitor cells (NPCs) and a microenvironment that inhibits the 
regeneration of neurons
 
[1]. Recent studies have demonstrated that the inhibition of axon 
regeneration after injuries to the central nervous system (CNS) were associated with several 
CNS myelin proteins, including Nogo-A, myelin-associated glycoprotein (MAG), and 
oligodendrocyte myelin glycoprotein (OMgp). These three proteins bind to the Nogo-66 
receptor (NgR1), which then leads to the downstream activation of RhoA (Ras homolog gene 
family, member A) via two transmembrane proteins, LINGO-1 and p75; these proteins inhibit 
the activity in neurons and their axons [2–4]. Jun N-terminal kinases (JNKs) are intracellular 
molecules related to stress stimuli. The activation of these molecules mediates many types of 
injury-induced apoptosis and plays a role in the regeneration of axons. However, the role of 
the JNK-signaling pathway in the presence of a brain infarction is still unclear. The 
administration of sNgR-Fc, a recombinant rat soluble NgR-Fc fusion protein
 
[5], has been 
found to block the interaction of myelin proteins with NgR1 effectively and to promote the 
regeneration of axons in rodent models of CNS injuries such as spinal cord injury [6–10]. A 
previous study has shown that anti-Nogo-A antibody promoted the behavioral outcome and 
corticospinal plasticity in a rat stroke model [11]. In this study, we established a stroke model 
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 in rats and observed the effects of sNgR-Fc on the axonal pathology and the involved 
RhoA/JNK signaling pathways after cortical infarction. 
 
Experimental Procedure 
Animals 
The animal experiments were approved by the Committee for the Use of Live Animals in 
Teaching and Research at the Sun Yat-sen University. All of the experiments were performed 
in a fully randomized and blinded fashion.  
Photothrombotic cortical injury  
Photothrombotic ischemia was induced in the rat parietal cortex using previously described 
methods [9,11,12] with the modifications as outlined below. Twenty seven male SD rats 
weighing 250 g were anesthetized by an intraperitoneal injection of ketamine (80 mg/kg) and 
xylazine (8 mg/kg). Dilute Rose-Bengal in saline (40 mg/kg body weight) was infused into 
the femoral vein. The portion of the skull exposed at 3 mm posteriorly to the bregma and 3 
mm laterally from the midline was illuminated with a cold, white light beam (Volpi Intralux 
6000, 150 W; Volpi AG, Schlieven, Switzerland) for 8 min at maximum output via a 
fiber-optic bundle with a 10 mm aperture. The animals were randomly grouped into 
sham-operation (operation + Rose-Bengal), PBS (operation + Rose-Bengal + PBS), or 
sNgR-Fc (operation + Rose-Bengal + sNgR-Fc) groups (n = 9 for each group). A solution of 
sNgR-Fc (400 μg/kg body weight) in 10μl PBS or equivalent PBS was only once injected 
into the ipsilateral ventricle using a 26-gauge sterile microsyringe 24 h after photothrombotic 
cortical injury [11]. The site of injection was at 1 mm posteriorly to the bregma and 1.5 mm 
laterally from the midline, and the depth of injection was about 3.5~4.0 mm. For each group, 
the whole cerebrum of 3 animals was collected 24 h after injury for tissue staining. The 
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 ipsilateral cortex of peripheral penumbra at 7 mm posteriorly to the bregma and 3 mm 
laterally from the midline of rats was collected at 27 d after injury for electron microscopy 
examination (n = 3 for each group) and for Western blotting (n = 3 for each group). 
 
Triphenyltetrazolium chloride staining 
To evaluate the extent of cortical infarction, we used 2, 3, 5-Triphenyltetrazolium chloride 
(TTC) to assess cerebral injury. At 24 h after PCI, the animals were sacrificed using an 
overdose of pentobarbital sodium (150 mg/kg, Alcon-Couvreur, Rijksweg, Puurs, Belgium). 
The brains were removed immediately and then were chilled at −30 °C for 4 min to slightly 
freeze the tissue. Two-mm coronal sections from the olfactory bulb to the cerebellum were 
prepared, stained with 1.5% TTC (Genetime) at 37 °C for 30 min, and fixed in 10% buffered 
formalin solution.  
Transmission electron microscopy 
Seven days after PCI, the peripheral penumbra at 7 mm posteriorly to the bregma and 3 mm 
laterally from the midline on the injury side was removed and immediately cut into 0.5 cm
3
 
cubes at 0 °C, fixed with 4% paraformaldehyde for 4 h, and washed with PBS. Then, the 
tissue was fixed with 2% osmic acid for 2 h, washed with pure water, dehydrated with a 
mixture of ethanol, propylene oxide, and resin, embedded in pure resin, and ultramicrocut 
and stained with uranyl acetate and lead citrate [13, 14]. The sections were observed under an 
HE-800 transmission electron microscope (Hitachi, Japan).  
Western blotting 
The cortex from the injury side was collected at 7 days after injury and homogenized in a 
lysis buffer (in mM: Tris, 10, pH 7.4; NaCl, 150; EDTA, 1; EGTA, 1; 10% protease inhibitor, 
1% phosphatase inhibitor), and incubated on ice for 30 min. The protein lysate was then 
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 centrifuged at 13,500 rpm for 30 min at 4 ℃. The supernatant was aliquoted and stored at 
−80 °C until its use. The supernatant was measured for its protein concentration using a 
Bio-Rad DC Protein Assay Kit (Bio-Rad Laboratories, CA, USA). A 40 μg aliquot of protein 
from each sample was subjected to 5–12% SDS–polyacrylamide gel electrophoresis and 
transferred onto a PVDF membrane. Each membrane was blocked with 5% non-fat milk and 
2% bovine serum albumin in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 h 
at room temperature and then probed with rabbit anti-p-JNK (Cell Signaling Technology, 
MA, USA), anti-p-c-JUN (Cell Signaling Technology), p-ATF-2 (Cell Signaling 
Technology), total-JNK (Cell Signaling Technology) and total-RhoA antibodies at 4 °C 
overnight. As a gel loading control, β-actin was used. After washing, the membranes were 
incubated for 2 h with horseradish peroxidase-conjugated goat anti-rabbit antibody (1:2000; 
DakoCytomation, Denmark). Its immunoreactivity was visualized using the Amersham 
enhanced chemiluminescence kit (Amersham, Piscataway, NJ, USA). The protein loading 
was controlled using the goat antibody against β-actin (C-11; Santa Cruz Biotechnology). 
The quantification of the results was performed by densitometry, and the results were 
analyzed as total integrated densitometric values (arbitrary units). The protein GTP-RhoA 
was pulled down using a RhoA activation assay kit, according to the manufacturer's 
instruction (Cytoskeleton, Denver, CO, USA) and assayed by Western blotting using an 
antibody against RhoA (Cytoskeleton). All experiments for Western blotting were performed 
with 3 animals in each group, and the samples were run on the gels as individual animals. 
Data and statistical analysis 
The values are presented as the mean ± SD. The statistical analyses was performed 
using Student’s t-test for comparisons between two groups or the one-way analysis of 
variance (ANOVA) followed by post-hoc tests (Student-Neuman-Keuls) for comparisons of 
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 more than two groups. The data were analyzed statistically with the software SPSS 12.0. The 
significance level was set at P < 0.05. 
 
Results 
Measurement of brain infarct volume and identification of blood brain barrier integrity 
After TTC staining, the rats in the sham group did not appear to have any infarctions (Fig. 
1b). However, the right parietal lobes of the rats 24 h after PCI presented pale infarctions that 
were bowl-shaped, with the bottom pointing to the lateral ventricle; these infarctions affected 
the entire cortex. The total infarct volumes were 297.1 ± 23.4 μl in the PBS group and 
285.4 ± 19.7 μl for the sNgR-Fc group respectively before the treatment. The locations of 
the infarctions were stable, and the infarctions showed similar volumes to those in the rats 
(Fig. 1). 
Pathological changes of axons 
The morphology of ischemic penumbra on the injury side was evaluated using TEM at 7 days 
after PCI. Compared with the normal axons observed in the sham group (Fig. 2a), more 
serious pathologies were observed in the PCI group (Fig. 2b). For the axons without a 
medulla sheath, many edemas, dilutions of cytoplasmic matrices, and axonal fusions or 
dissolutions were found. Occasionally, we observed that oligodendrocytes appeared to 
“swallow” the axons (Fig. 2b). For axons with a medulla sheath, compared with the sham 
group, thickening or shrinking was more in the axoplasm of the fibers, and amyloidosis and 
swollen axons were observed at a higher rate. In addition, the axolemma were found to be 
separated from the inner layers of the myelin (Fig. 2e). In addition, there were only minor 
pathological changes, including slight nuclear edemas with complete nucleoli, slightly 
swollen mitochondria, and slightly widened endoplasmic reticula with complete ribosomes 
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 and Golgi bodies. In unmyelinated axons, there were some axonal edemas, axonal 
deformities, and dilutions of cytoplasmic matrices; in addition, there were no axonal fusions 
or cytophagic effects of oligodendrocytes (Fig. 2c). In myelinated axons, the morphology of 
axons was almost normal. There was little demyelination and no amyloidosis of the myelin 
sheath was found (Fig. 2f). Compared with normal synapses (Fig. 2g), the synaptic cleft 
widened, and there was edema in the PBS group (Fig. 2h). However, no clear edema or 
widening of the synaptic cleft was observed in the group that received the sNgR-Fc treatment 
(Fig. 2i). 
sNgR-Fc inhibited RhoA signal pathway 
The level of GTP-RhoA in the PBS group was significantly higher than that in the 
sham-operation group (P <0.05). After treatment with sNgR-Fc, the level of GTP-RhoA was 
significantly decreased. Moreover, the level of Total-RhoA was not different among the three 
groups (Fig.3, Table 1). These data indicate that sNgR-Fc could decrease the activation of 
RhoA. 
sNgR-Fc inhibit the activation of SAPK/JNK signal pathway 
The levels of p-JNK1, 2 and its downstream targets, p-c-JUN and p-ATF-2, in the cortex 
around the infarcts in the PCI group were significantly higher compared with those in the 
sham operation group (P < 0.05). In contrast, the cortex in the sNgR-Fc-treated group showed, 
on average, reductions in the levels of p-JNK1, 2, p-c-JUN and p-ATF-2 to their basal levels 
(P < 0.05). The levels of total JNK1, 2 were not different among the three groups (P > 0.05). 
These results demonstrate that the cortical infarction injury activates the SAPK/JNK signal 
pathway and that treatment with sNgR-Fc has the potential to decrease or prevent this 
activation (Fig.3, Table 1). 
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 Discussion 
Watson et al reported a stroke model induced by a photochemical method in 1985 [12]. The 
principle underlying this model was based on a photochemical reaction. Following the 
injection of a potent photosensitive agent into rats, ischemic lesions were formed by 
irradiating the left parietal convexities of the exposed skulls under a light with a specific 
wavelength. Free radicals were released, damaging the endothelium of the cerebral vessels 
and inducing platelet aggregation. Furthermore, this pathology causes thrombosis in cerebral 
parenchymal vessels and results in irreversible hypoxic-ischemic brain damage (HIBD). 
Because of the advantages of a stable location and infarction volume, a low mortality rate, 
and a good replication rate, the stroke model is widely used in current studies of brain injury. 
In this study, we successfully induced a cortical ischemic infarction model in rats in which 
the BBB was also damaged. The primary pathological features of stroke were induced, and 
the volumes of infarction were consistent. No infarction and no burn were observed in the 
sham-group, indicating that the light stimulation alone did not induce the infarction and that it 
acts as a good control. 
Delayed neuron death (DND) is an important pathology of cerebral ischemia and 
cerebral degenerative disease. Cell apoptosis was the primary DND pattern after an acute 
HIBD, which aggravated the injury of sub-acute or chronic cerebral infarction [15, 16]. In our 
study, axonal pathologies were observed via the TEM at 7 days after PCI, including many 
edemas in the axoplasm of axons that have no medulla sheath, and thickening or shrinkage in 
the sheaths of the axons that have a medulla sheath. However, these conditions improved 
after sNgR-Fc treatment. The administration of the soluble NgR1 fusion protein (sNgR-Fc) 
effectively blocked the interaction of myelin molecules with NgR1 and promoted axon 
sprouting and functional recovery after spinal cord injuries[7–9], or dorsal root rhizotomy[10]. 
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 A previous study found that Nogo-A is involved in the secondary axonal degeneration of the 
thalamus with cerebral infarction in hypertensive rats [17] and after a focal ischemic stroke 
[18]. Anti–Nogo-A antibody improved behavioral outcome and corticospinal plasticity but 
did not decrease the infarct volume after experimental stroke [11]. In this study, sNgR-Fc did 
not cause any difference on infarct volume, but still provided protection of axons as observed 
in TEM. 
Nogo-A, MAG and OMgp were considered to be the inhibitory factors of axonal 
regeneration in the CNS. NgR1 mediates their inhibitory effect via two co-receptors, p75 and 
Lingo-1, and transduces the signals via RhoA and its downstream pathways [19, 20]. In this 
study, the level of the GTP-RhoA protein in the model group was significantly higher than 
that of the sham-operation group. With the treatment of sNgR-Fc, the level of the GTP-RhoA 
protein was significantly decreased, suggesting that sNgR-Fc may promote axonal recovery 
by preventing the activation of RhoA after cerebral infarction.  
The stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) signaling 
pathway is a powerful signaling pathway under the stresses of ultraviolet light, radiation and 
inflammation [21–23]. In publications on neuronal apoptosis, some of the proteins in the 
mitogen-activated protein kinases (MAPK) signaling pathways have been well-studied in 
recent years. The MAPK signaling pathway is a family of serine/threonine kinases that 
include three members: the extracellular signal-regulated protein kinases (ERK), JNK and 
p38 [24]. The JNK/SAPK and p38 are induced by cellular stress and some of the cytokines. 
The JNK protein can be activated by many stress stimulators, such as lipopolysaccharide 
(LPS), tumor necrosis factor-α(TNF-α), interleukin (IL)-1 or ultraviolet light. Activation of 
the JNK signaling pathway is related to cell apoptosis [24]. Following its activation, JNKs 
may phosphorylate specific sites of some of the transcription factors, such as ATF-2, SAP-1 
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 and Elk-1, and increase the expression of genes, subsequently increasing the synthesis of 
proteins that may participate in the apoptosis pathway and cause cell death [25]. We found 
high levels of p-JNK，p-c-JUN and p-ATF-2 after stroke injury, indicating that cortical 
infarction activates the SAPK/JNK signal pathway and leads to the pathology of tissues and 
cells. The administration of sNgR-Fc decreased the activation of those proteins, suggesting 
that sNgR-Fc has the potential to prevent or decrease the activation of the SAPK/JNK signal 
pathway. We previously identified that sNgR-Fc binds to Nogo66, OMgp, and MAG [9] and 
inhibited the Nogo66-NgR interaction [6]. sNgR-Fc may protect axons by inhibiting the 
interaction of Nogo-A-NgR1 after stroke injury, decreasing the activation of RhoA and JNK. 
A schematic diagram illustrating the proposed mechanism for sNgR-Fc on axons in stroke is 
shown in Figure 4: In normal conditions, the cortex expresses low levels of Nogo-A and 
NgR1. However, cortical infarction under stroke injury increases the expression of Nogo-A 
and NgR1. Nogo-A activates RhoA and JNK signaling pathways via interacting with NgR1 
and then results in pathological changes on axons. sNgR-Fc perturbs the interaction of 
Nogo-A and NgR1, decreases the activation of RhoA and JNK signaling pathways and 
relieving the pathological changes of axons.  
RhoA regulates the intracellular microfilament associated with cell proliferation through a 
series of complex mechanisms [26]. Previous studies have observed that RhoA stimulates Jun 
expression through the Rho-associated kinase (ROCK), which phosphorylates c-Jun and 
ATF2 after binding to the c-Jun promoter [27]. In this study, we observed that changes in the 
expression of p-JNK, p-c-Jun and p-ATF-2 were consistent with changes in the GTP-RhoA 
level following both the cerebral infarction and the sNgR-Fc treatment. These findings 
suggest that sNgR-Fc can relieve the axonal pathology partially by decreasing the activation 
of the SAPK/JNK signal pathways. 
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 In summary, pathological changes in axons were induced by the cerebral 
hypoxia-ischemia for an extended period after the cortical infarction. This phenomenon may 
be associated with the activation of RhoA/ROCK/JNK/c-Jun signaling pathways. We 
determined that an NgR1 antagonist, sNgR-Fc, alleviated axonal pathology changes and 
prevented the activation of RhoA/ROCK/JNK/c-Jun signaling pathways. Further studies 
should be performed before this treatment is used in a clinical study. 
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 Figure Legends 
Figure 1. The morphology and characteristics of the rat brain after a stroke induced by 
photothrombotic cortical injury. (a) Representative photographs of the coronal brain 
sections stained with 2,3,5-triphenyltetrazolium chloride in rats, (b) sham-operated rats, (c) 
and photothrombotic cortical injury (PCI) rats. White indicates the infarct area (arrow).  
 
Figure 2. The protective effect of sNgR-Fc on axon neurons under transmission electron 
microscope after stroke injury. Ultrastructural appearances of morphology of axons in 
sham-operated, PBS and sNgR-Fc groups: (a) Normal unmyelinated axons in sham-operated 
group; (b) Extensive edema, axon deformity, dilution of cytoplasmic matrices and axonal 
fusion in stroke model; (c) Slight edema and dilution of cytoplasmic matrices with the 
treatment of sNgR-Fc in stroke model; (d) Normal myelinated axons in sham-operated group; 
(e) Thickening, shrinking or amyloidosis was more in stroke model; (f) Little demyelination 
and no amyloidosis of the myelin sheath were found with the treatment of sNgR-Fc in stroke 
model; (g) Normal synapses in the sham-operated group; (h) Widened and swollen synaptic 
cleft in stroke model; (i) Approximately normal synapses with the treatment of sNgR-Fc in 
stroke model. Arrows show the changes in axons. 
 
Figure 3. The RhoA, SAPK/JNK signaling pathways after stroke injury and with the 
treatment of sNgR-Fc under Western blotting. The levels of p-JNK，p-c-JUN, p-ATF-2 
and GTP-RhoA increased after stroke injury. Treatment with sNgR-Fc decreased the levels of 
p-JNK, p-c-JUN, p-ATF-2 and GTP-RhoA to normal levels. 
 
Figure 4. The diagram of the signaling pathways involved in the sNgR-Fc on axons after 
stroke injury. In the normal condition, there is low level of Nogo-A and NgR1 in the cortex. 
However, the expression of Nogo-A and NgR1 is increased under stroke injury. The increased 
Nogo-A binds with NgR1 to activate the downstream pathways of RhoA and JNK, and then 
results in axonal pathology. The treatment of sNgR-Fc inhibits the interaction of Nogo-A and 
NgR1, decreases the activation of RhoA and JNK signaling pathways and then relieves 
axonal pathology.  
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Table 1 The density of the key proteins of RhoA and SAPK/JNK signal pathway  
 
 
 
 
 
 
 
 
▲
P<0.05 vs Sham-operated group; 
■
P<0.05 vs PBS group, Mean ±SD, n = 3） 
 
0.98±0.12 0.99±0.11 1±0.09 Total-JNK2 
1.01±0.08 1.01±0.09 1.0±0.08 Total-JNK1 
1.02±0.15▲■ 1.73±0.12▲ 1.0±0.14 p-JNK2 
1.30±0.31▲■ 2.24±0.27▲ 1.0±0.29 p-JNK1 
1.12±0.058▲■ 1.39±0.139▲ 1.0±0.062 p-c-JUN 
1.53±0.22▲■ 2.19±0.24▲ 1.0±0.12 p-ATF-2 
0.98±0.10 0.97±0.11 1.0±0.09 Total-RhoA 
1.10±0.13▲■ 1.73±0.16▲ 1.0±0.14 GTP-RhoA 
sNgR-Fc PBS  
Sham-operated  
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